When HCC cells were co-treated with ATAD2 siRNA and specific inhibitors of p53 (PFT-α and PFT-μ) or p38 (p168316), we observed that both p53 and p38 inhibitors could reverse the decrease in cell viability caused by ATAD2 suppression in HepG2 cells (Figure 4D). This evidence concerns the gene ATAD2 and hepatocellular carcinoma.